Astana Biomed Group, an authorized Abcam distributor in Central Asia

Anti-SARS-CoV-2 Spike RBD antibody [CV30] - BSA and Azide free (ab277515)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Human monoclonal [CV30] to SARS-CoV-2 Spike RBD - BSA and Azide free
  • Suitable for: Indirect ELISA

Overview

  • Product name

    Anti-SARS-CoV-2 Spike RBD antibody [CV30] - BSA and Azide free
    See all SARS-CoV-2 Spike RBD primary antibodies

  • Description

    Human monoclonal [CV30] to SARS-CoV-2 Spike RBD - BSA and Azide free

  • Host species

    Human

  • Tested applications

    Suitable for: Indirect ELISAmore details

  • Immunogen

    Tissue, cells or virus. This information is proprietary to Abcam and/or its suppliers.

  • General notes

    CV30 cross-reacts with both SARS-CoV-2 Spike RBD and Ectodomain. CV30 demonstrates significant neutralising ability in in-direct ELISA, measuring competitive binding of CV30 to SARS-CoV-2 Spike RBD in the presence of human ACE2.

    This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact orders@abcam.com.

    ab277515 is the carrier-free version of ab277513. This format is designed for use in antibody labeling, including fluorochromes, metal isotopes, oligonucleotides, enzymes.

    Our carrier-free formats are supplied in a buffer free of BSA, sodium azide and glycerol for higher conjugation efficiency.

    Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with

    ab277515 is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm.

    Maxpar® is a trademark of Fluidigm Canada Inc.

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

Properties

Images

  • Indirect ELISA - Anti-SARS-CoV-2 Spike RBD antibody [CV30] - BSA and Azide free (ab277515)
    Indirect ELISA - Anti-SARS-CoV-2 Spike RBD antibody [CV30] - BSA and Azide free (ab277515)

    This data was produced using the same clone but in a different formulation, ab277513.

    Indirect ELISA showing ab277513 (CV30) binding to purified His-tagged SARS-CoV2-RBD. Plates were coated with 100ng/well purified protein and binding of ab277513 assessed in serial dilution from 100ng/ml primary antibody in duplicate. Binding was detected using ab98624, an anti-human Fc secondary conjugated to HRP. Data are represented as the mean and error bars represent standard deviation.

  • Indirect ELISA - Anti-SARS-CoV-2 Spike RBD antibody [CV30] - BSA and Azide free (ab277515)
    Indirect ELISA - Anti-SARS-CoV-2 Spike RBD antibody [CV30] - BSA and Azide free (ab277515)

    This data was produced using the same clone but in a different formulation, ab277513.

    Indirect ELISA showing ab277513 (CV30) binding to ab272105 (recombinant human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (sheep Fc fusion)). Plates were coated with 100ng/well ab272105 and binding of ab277513 assessed in serial dilution from 100ng/ml primary antibody in duplicate. Binding was detected using ab98624, an anti-human Fc secondary conjugated to HRP. Data are represented as the mean and error bars represent standard deviation.

  • Indirect ELISA - Anti-SARS-CoV-2 Spike RBD antibody [CV30] - BSA and Azide free (ab277515)
    Indirect ELISA - Anti-SARS-CoV-2 Spike RBD antibody [CV30] - BSA and Azide free (ab277515)

    This data was produced using the same clone but in a different formulation, ab277513.

    Indirect competition ELISA showing competitive binding of ab277513 (CV30) to purified Fc-tagged SARS-CoV2-RBD in the presence of 2nM His-tagged human ACE2. Plates were coated with 100ng/well SARS-CoV2-RBD and binding of the recombinant ACE2 determined in duplicate in the presence of a serial dilution (from 330nM) of primary antibody. His-tagged ACE2 binding was detected using ab1187, an anti-His tag secondary conjugated to HRP. Data are represented as the mean and error bars represent standard deviation.

  • Indirect ELISA - Anti-SARS-CoV-2 Spike RBD antibody [CV30] - BSA and Azide free (ab277515)
    Indirect ELISA - Anti-SARS-CoV-2 Spike RBD antibody [CV30] - BSA and Azide free (ab277515)

    This data was produced using the same clone but in a different formulation, ab277513.

    Indirect competition ELISA showing competitive binding of ab277513 (CV30) to ab272105 (recombinant human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (sheep Fc fusion)) in the presence of 2nM His-tagged human ACE2. Plates were coated with 100ng/well ab272105 and binding of the recombinant ACE2 determined in duplicate in the presence of a serial dilution (from 330nM) of primary antibody. His-tagged ACE2 binding was detected using ab1187, an anti-His tag secondary conjugated to HRP. Data are represented as the mean and error bars represent standard deviation.

  • Anti-SARS-CoV-2 Spike RBD antibody [CV30] - BSA and Azide free (ab277515)
    Anti-SARS-CoV-2 Spike RBD antibody [CV30] - BSA and Azide free (ab277515)

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

© 2021 Astana Biomed Group LLP. All rights reserved.